These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 25187348)

  • 1. Meta-analysis of randomized phase II trials to inform subsequent phase III decisions.
    Burke DL; Billingham LJ; Girling AJ; Riley RD
    Trials; 2014 Sep; 15():346. PubMed ID: 25187348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety outcomes in meta-analyses of phase 2 vs phase 3 randomized trials: Intracranial hemorrhage in trials of bolus thrombolytic therapy.
    Eikelboom JW; Mehta SR; Pogue J; Yusuf S
    JAMA; 2001 Jan 24-31; 285(4):444-50. PubMed ID: 11242429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The inclusion of real world evidence in clinical development planning.
    Martina R; Jenkins D; Bujkiewicz S; Dequen P; Abrams K;
    Trials; 2018 Aug; 19(1):468. PubMed ID: 30157904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bayesian methods for setting sample sizes and choosing allocation ratios in phase II clinical trials with time-to-event endpoints.
    Cotterill A; Whitehead J
    Stat Med; 2015 May; 34(11):1889-903. PubMed ID: 25620687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mixtures of prior distributions for predictive Bayesian sample size calculations in clinical trials.
    Brutti P; De Santis F; Gubbiotti S
    Stat Med; 2009 Jul; 28(17):2185-201. PubMed ID: 19462415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing the success probability of a Phase III clinical trial based on Phase II data.
    Su Z
    Contemp Clin Trials; 2010 Nov; 31(6):620-3. PubMed ID: 20713180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beta-blockers for suspected or diagnosed acute myocardial infarction.
    Safi S; Sethi NJ; Nielsen EE; Feinberg J; Jakobsen JC; Gluud C
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012484. PubMed ID: 31845756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing the data combination rule for seamless phase II/III clinical trials.
    Hampson LV; Jennison C
    Stat Med; 2015 Jan; 34(1):39-58. PubMed ID: 25315892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
    Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
    Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Seamlessly expanding a randomized phase II trial to phase III.
    Inoue LY; Thall PF; Berry DA
    Biometrics; 2002 Dec; 58(4):823-31. PubMed ID: 12495136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using phase II data for the analysis of phase III studies: An application in rare diseases.
    Wandel S; Neuenschwander B; Röver C; Friede T
    Clin Trials; 2017 Jun; 14(3):277-285. PubMed ID: 28387537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative decision-making in randomized Phase II studies with a time-to-event endpoint.
    Huang B; Talukder E; Han L; Kuan PF
    J Biopharm Stat; 2019; 29(1):189-202. PubMed ID: 29969380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized two-stage design for phase II clinical trials based on a Bayesian predictive approach.
    Cellamare M; Sambucini V
    Stat Med; 2015 Mar; 34(6):1059-78. PubMed ID: 25545805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BASIC: A Bayesian adaptive synthetic-control design for phase II clinical trials.
    Jiang L; Thall PF; Yan F; Kopetz S; Yuan Y
    Clin Trials; 2023 Oct; 20(5):486-496. PubMed ID: 37313712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practical guidelines for adaptive seamless phase II/III clinical trials that use Bayesian methods.
    Kimani PK; Glimm E; Maurer W; Hutton JL; Stallard N
    Stat Med; 2012 Aug; 31(19):2068-85. PubMed ID: 22437262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Some thoughts on sample size: a Bayesian-frequentist hybrid approach.
    Gordon Lan KK; Wittes JT
    Clin Trials; 2012 Oct; 9(5):561-9. PubMed ID: 22865839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bayesian optimal phase II designs with dual-criterion decision making.
    Zhao Y; Li D; Liu R; Yuan Y
    Pharm Stat; 2023; 22(4):605-618. PubMed ID: 36871961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design issues in randomized phase II/III trials.
    Korn EL; Freidlin B; Abrams JS; Halabi S
    J Clin Oncol; 2012 Feb; 30(6):667-71. PubMed ID: 22271475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.